Introduction
Breast cancer is a malignant growth that usually begins in the milk ducts or lobules of the breast. It is one of the most frequently diagnosed cancers worldwide, with roughly 2.3 million new cases each year according to global estimates. Early detection and stage-appropriate treatment substantially improve outcomes.
Most cases occur in women over 50, but younger women and, rarely, men can be affected. Risk rises with age, certain inherited gene variants, family history, prior chest radiation, and hormonal or lifestyle factors—yet many people with few known risks still develop the disease.
Modern care classifies tumours by where they start (for example invasive ductal or lobular carcinoma) and by biology (hormone-receptor and HER2 status). Those markers guide surgery, radiation, chemotherapy, hormone therapy, targeted drugs, and immunotherapy.
This overview is educational. Treatment plans are individualized by oncology teams after imaging, biopsy, staging, and discussion of goals and side effects.
Overview
Breast cancer is not a single disease; subtypes behave and respond differently to treatment.
Screening mammography can find cancer before a lump is felt; symptoms still warrant prompt evaluation even between screens.
Multidisciplinary care—surgery, medical oncology, radiation oncology, pathology, and supportive services—improves coordination and results.
- Common cancer; early stage disease often highly treatable
- Main risks: female sex, older age, family history, BRCA/PALB2 and related mutations
- Types by origin (IDC, ILC, rarer subtypes) and by receptors (HR+, HER2+, triple-negative)
- Diagnosis: mammogram, ultrasound, MRI as needed, and tissue biopsy
- Treatment may combine surgery, radiation, and systemic medicines
- Survivorship care addresses recurrence surveillance and late effects
What happens in the body
Genetic changes in breast epithelial cells allow uncontrolled growth, invasion of nearby tissue, and sometimes spread to lymph nodes or distant organs. Hormones (oestrogen/progesterone) or HER2 signalling can drive growth in receptor-positive tumours.
Triple-negative cancers lack ER, PR, and HER2 and often rely more on chemotherapy and, in selected cases, immunotherapy. Inflammatory breast cancer is a rare aggressive presentation with skin oedema and redness from dermal lymphatic involvement.
- Ductal or lobular cells acquire mutations that promote growth
- Hormone and HER2 pathways fuel many tumours
- Invasion and metastasis define staging and prognosis
- Biology testing on biopsy directs precision therapies
Signs and symptoms
Not every cancer causes early symptoms. Seek evaluation for any persistent breast change, including:
- New lump or thickening in the breast or underarm
- Change in breast size or shape
- Skin dimpling, puckering, or “orange-peel” texture
- Nipple inversion, scaling, or unexplained discharge (especially bloody)
- Redness, warmth, or swelling of the breast skin
- Persistent breast or nipple pain that is new for you
- Swollen lymph nodes under the arm or above the collarbone
- Rare inflammatory pattern: rapid swelling, redness, and tenderness
- In men: firm lump behind the nipple or areola
- Advanced disease: bone pain, unexplained weight loss, breathlessness, or neurologic symptoms from spread
- Many lumps are benign—but new changes still need clinical assessment
- Normal mammogram does not erase a new suspicious clinical finding—ask for further tests if concern persists
Causes and risk factors
Exact triggers vary; these factors increase probability rather than guarantee disease:
- Female sex and increasing age (most diagnoses after 50)
- First-degree relative with breast cancer
- Inherited mutations such as BRCA1, BRCA2, or PALB2
- Chest radiation at a young age
- Early menarche or late menopause (longer hormone exposure)
- Post-menopausal obesity
- Combined menopausal hormone therapy in some users
- Alcohol use, physical inactivity, and never having breastfed (modest contributors)
- Personal history of certain atypical breast lesions
- Male breast cancer risk rises with BRCA2 and hormonal/testicular disorders
- Most cases are not clearly hereditary
- Absence of risk factors does not mean zero risk
Diagnosis and evaluation
Evaluation confirms cancer type, receptors, and stage:
- Clinical breast exam and history
- Digital mammography and, when useful, 3D tomosynthesis
- Breast ultrasound to characterize lumps or guide biopsy
- Breast MRI for dense breasts, staging, or high-risk screening as indicated
- Core needle biopsy (preferred) with marker clip when appropriate; FNAC in selected settings
- Pathology for histologic type, grade, ER/PR, HER2, and Ki-67 as ordered
- Genomic assays (for example Oncotype DX or similar) in selected early HR+ cases to refine chemo benefit
- Staging imaging (CT, bone scan, PET-CT) when clinically indicated
- Genetic counselling/testing for hereditary syndromes when family or personal history warrants
Treatment and management
Therapy is sequenced as neoadjuvant (before surgery), adjuvant (after), or for metastatic control. Plans depend on stage and subtype—never self-start oncology drugs:
- Breast-conserving surgery (lumpectomy) plus radiation for many early tumours
- Mastectomy when needed for size, multicentricity, contraindications to radiation, or preference; reconstruction options exist
- Sentinel lymph-node biopsy; axillary dissection only when necessary
- Radiation therapy (often hypofractionated courses) to reduce local recurrence
- Chemotherapy before or after surgery, or for advanced disease
- Endocrine therapy (tamoxifen or aromatase inhibitors) for HR+ disease, often 5–10 years
- HER2-targeted agents (for example trastuzumab/pertuzumab) when HER2-positive
- CDK4/6 inhibitors, PARP inhibitors, antibody–drug conjugates, and immunotherapy in selected advanced or biomarker-defined settings
- Supportive care: antiemetics, growth-factor support, physiotherapy for lymphoedema, nutrition, and psycho-oncology
- Clinical-trial options when available and appropriate
Prevention, self-care, and lifestyle
Not every condition is fully preventable, but the steps below may lower risk or recurrence:
- Screening mammograms starting at an age set by guidelines and personal risk (often around 40; earlier if high risk)
- Maintain healthy weight, especially after menopause
- Regular physical activity (about 150 minutes moderate exercise weekly as a common target)
- Limit alcohol; avoid tobacco
- Breastfeed if possible and desired
- Discuss risk-reducing medication or surgery only after formal high-risk assessment and counselling
- Genetic counselling when family history is strong
Possible complications
Delay, missed care, or unsafe self-medication can raise the chance of complications in some cases:
- Local recurrence or distant metastasis if disease progresses
- Lymphoedema after nodal surgery or radiation
- Treatment toxicities: fatigue, neuropathy, cardiotoxicity, bone loss, premature menopause
- Infection or wound issues after surgery
- Body-image and sexual-health concerns
- Anxiety, depression, or fear of recurrence
- Secondary cancers rare but discussed for some therapies
- Financial and work disruption during prolonged treatment
When to see a doctor or seek emergency care
Seek prompt medical advice or emergency care if any of the following apply—it is safer not to wait and see:
- Any new breast lump, skin change, or nipple discharge
- Red, swollen, warm breast—urgent evaluation
- Abnormal screening mammogram requiring recall
- Strong family history—discuss earlier screening or genetics
- During treatment: fever with low blood counts, chest pain, severe shortness of breath, uncontrolled vomiting, or sudden arm swelling
- Post-treatment new bone pain, persistent cough, neurologic change, or new breast/chest-wall findings
Living with the condition
After active treatment, follow the survivorship schedule for exams and imaging. Report new symptoms early rather than waiting for the next routine visit.
Rehabilitation, graded exercise, and nutrition support help recovery. Lymphoedema prevention education matters if nodes were treated.
Emotional ups and downs are common; counselling and peer support are part of good care, not optional extras.
Frequently asked questions
What are early signs of breast cancer?
A new lump, shape change, skin dimpling, nipple changes or discharge, and unexplained redness or swelling. Most lumps are not cancer, but they should be checked.
At what age should screening start?
Many guidelines suggest regular mammograms from about age 40. High-risk people may start earlier—confirm a plan with your clinician.
Is breast cancer curable if found early?
Early-stage disease has very high survival rates with modern treatment—often well above 90% in many series—and more options for breast conservation.
Can men get breast cancer?
Yes, though it is uncommon (under 1% of cases). Men should seek care for chest lumps or nipple changes.
Does breast pain mean cancer?
Pain alone is more often benign, but new focal pain with other changes should still be evaluated.
Will I need chemotherapy?
Not always. Need depends on stage, receptors, grade, and sometimes genomic tests. Some people do well with surgery plus endocrine therapy alone.
What is the difference between lumpectomy and mastectomy?
Lumpectomy removes the tumour with a margin of tissue; mastectomy removes the whole breast. Radiation usually follows lumpectomy. Choice depends on tumour factors and personal preference.
Is breast cancer hereditary?
Most cases are not inherited. About 10–15% relate to family risk patterns; BRCA and related genes markedly raise risk when present.
Important caution
This article is for general health education only. It is not personal oncology advice or a treatment prescription.
Breast cancer care should follow biopsy-confirmed diagnosis, staging, and shared decision-making with qualified specialists.
Seek urgent care for rapidly progressive breast inflammation, neurologic deficits, severe breathing trouble, or fever during chemotherapy.